Pablo Legorreta, Royalty Pharma CEO (David Paul Morris/Bloomberg via Getty Images)
Royalty Pharma pays Ferring $300M for 5% royalty on sales of cancer gene therapy Adstiladrin
Ferring Pharmaceuticals is pulling in $300 million and a potential $200 million milestone from Royalty Pharma in exchange for a 5 …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
